Study of enfortumab vedotin for advanced thyroid cancers and NUT carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called enfortumab vedotin for people with certain advanced thyroid cancers or NUT carcinoma that have not responded to other treatments. The drug is given by IV and aims to shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these thyroid cancers that has spread or cannot be removed: differentiated thyroid cancer that no longer responds to radioactive iodine, anaplastic thyroid cancer, medullary thyroid cancer, or NUT carcinoma.
- You have tried at least one previous treatment (like surgery, radiation, chemotherapy, or targeted therapy), but it is no longer working.
- You have not previously taken enfortumab vedotin or a similar drug.
- You are 18 years or older.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
This trial tests a drug called enfortumab vedotin for people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Hear when a new Metastatic NUT Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.